Abstract: The treatment landscape for chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) has been revolutionized by targeted oral agents, particularly Bruton’s tyrosine kinase inhibitors (BTKis) and BCL2 inhibitors (BCL2is). However, patients who become "double refractory" to both classes of drugs face a very poor prognosis with limited therapeutic options. Resistance is frequently driven by acquired mutations in the BTK protein, such as C481S and L528W, which abrogate the binding of covalent and non-covalent inhibitors. Catadegbrutinib (BGB-16673) is a novel, orally administered proteolysis-targeting chimera (PROTAC) designed to overcome these resistance mechanisms by completely degrading the BTK protein rather than merely inhibiting its kinase activity. Early clinical data demonstrate that BGB-16673 is highly active in heavily pretreated CLL/SLL patients, including those with high-risk genetic features and known BTK mutations, while maintaining a tolerable safety profile. This review synthesizes the pharmacological activity, molecular mechanism, structural rationale, current limitations, and future perspectives of Catadegbrutinib in the treatment of CLL and SLL.
1. Introduction
Chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) are characterized by the clonal expansion of malignant B-cells, driven largely by aberrant B-cell receptor (BCR) signaling and impaired apoptosis [1][2]. Over the past decade, the standard of care has shifted from traditional chemoimmunotherapy to targeted oral agents, specifically covalent and non-covalent Bruton’s tyrosine kinase inhibitors (BTKis) and BCL2 inhibitors (BCL2is) like venetoclax [1][2]. While these therapies are highly effective, a significant clinical challenge arises when patients relapse. Patients who progress after treatment with both a covalent BTKi and a BCL2i are termed "double refractory." This population has a very poor prognosis, a high risk of Richter’s transformation, and limited effective treatment options [1].
Disease progression on BTKis is most frequently driven by acquired mutations in the BTK protein. Covalent BTKis (e.g., ibrutinib, acalabrutinib, zanubrutinib) are often rendered ineffective by the C481S mutation, which disrupts irreversible drug binding [1][2]. Non-covalent BTKis (e.g., pirtobrutinib) were developed to overcome this, but secondary mutations such as L528W and T474I have subsequently emerged, conferring cross-resistance to both classes of inhibitors [1][2]. To address this unmet clinical need, BTK protein degraders have emerged as a novel therapeutic class. Catadegbrutinib (BGB-16673) is a first-in-class, orally available PROTAC that targets BTK for proteasomal degradation, offering a promising strategy to bypass inhibitor-resistant mutations in CLL/SLL [1][2][3].
2. Pharmacological Activity
Preclinical models have demonstrated that BGB-16673 effectively suppresses tumor growth in lymphoma xenografts and induces rapid, substantial, and sustained reduction of BTK protein levels in both peripheral blood and tumor tissue [1]. Pharmacokinetic studies in rats show an elimination half-life ranging from 7.2 to 10 hours. The compound is highly protein-bound and is metabolized by Cytochrome P450 3A (CYP3A). Interestingly, BGB-16673 exhibits a longer duration of response compared to traditional inhibitors like ibrutinib and pirtobrutinib, suggesting a disconnect between its pharmacokinetics and pharmacodynamics; the drug provides a lasting therapeutic effect even after it has been eliminated from circulation [1].
Clinically, BGB-16673 is being evaluated in the Phase 1/2 CaDAnCe-101 dose-escalation and expansion study (NCT05006716) for relapsed/refractory B-cell malignancies. In a cohort of 49 heavily pretreated CLL/SLL patients (median of 4 prior therapies, with 92% having received a covalent BTKi and 76% a BCL2i), BGB-16673 demonstrated an impressive overall response rate (ORR) of 72% to 78% [1][3]. Responses were robust across high-risk subgroups, including patients with unmutated IGHV (82%), TP53 mutations or del(17p) (60%), complex karyotypes (47%), and documented prior BTK or PLCG2 mutations [1].
The safety profile of BGB-16673 appears tolerable and comparable to other BTK-targeted agents. The most frequently reported adverse events include fatigue (35%), contusion (29%), diarrhea (27%), anemia (22%), and neutropenia (22%). Notably, no cases of atrial fibrillation or hypertension—common adverse events associated with traditional BTKis—have been reported to date [1].
3. Molecular Mechanism of Action
Catadegbrutinib (BGB-16673) operates via an "event-driven" pharmacological mechanism, distinct from the "occupancy-driven" mechanism of traditional kinase inhibitors [1]. As a PROTAC, it is a heterobifunctional molecule that does not merely block the kinase active site but completely removes the protein from the cell [2].
The molecule works by simultaneously binding to the target protein (BTK) and an E3 ubiquitin ligase (cereblon). This binding forms a ternary complex that brings the E3 ligase into close proximity with BTK. The E3 ligase then catalyzes the transfer of ubiquitin molecules to lysine residues on the BTK protein. This polyubiquitination tags BTK for recognition and subsequent degradation by the cell's ubiquitin-proteasome system [1][2]. Following the degradation of BTK, the PROTAC molecule is recycled and can engage in multiple subsequent rounds of targeted protein degradation [1].
By degrading the entire BTK protein, BGB-16673 eliminates all of its functions, including its enzymatic kinase activity and its non-enzymatic scaffolding role, thereby robustly inhibiting downstream BCR signaling pathways (such as NF-κB and RAS-RAF-MEK-ERK) [1]. Crucially, this mechanism allows BGB-16673 to degrade both wild-type BTK and mutant forms of BTK that confer resistance to covalent and non-covalent inhibitors [1][2].
4. Structure-Activity Relationship (SAR)
The structural design of BGB-16673 is foundational to its ability to overcome clinical resistance. The molecule consists of three essential components: a BTK-binding moiety (the target ligand), a linker, and an E3 ubiquitin ligase-binding moiety (the recruiter) [1][2].
Traditional covalent inhibitors rely on binding to the C481 residue, while non-covalent inhibitors rely on specific spatial conformations within the ATP-binding pocket. Mutations such as C481S disrupt covalent bonds, and mutations like L528W introduce bulky steric hindrances that prevent the binding of inhibitors like ibrutinib and pirtobrutinib [2]. The bifunctional structure of PROTACs like BGB-16673 allows them to accommodate these steric changes. Because PROTACs rely on transient binding to trigger ubiquitination rather than sustained active-site occupancy, the BTK-binding moiety of BGB-16673 can successfully engage mutant BTK conformations long enough to induce degradation [1][2]. Furthermore, BGB-16673 specifically utilizes a cereblon (CRBN)-binding element to recruit the E3 ligase, a design choice that has proven highly effective for BTK degradation in B-cell malignancies [1][2].
5. Current Limitations
Despite its promise, the clinical application of BGB-16673 faces several limitations and emerging challenges:
Emerging Resistance: While BGB-16673 overcomes common BTK mutations, novel resistance mechanisms are already being identified. A recent clinical case report detailed a patient with CLL who developed a new BTK-A428D mutation during treatment with BGB-16673, leading to disease progression [1][2]. The A428D mutation is hypothesized to be a kinase-impaired mutation driven by the selective pressure of the degrader, though definitive functional studies confirming the exact mechanism of resistance are still required [2].
Pharmacokinetic Interactions: BGB-16673 is metabolized by the CYP3A enzyme system, meaning that co-administration with CYP3A inhibitors or inducers could significantly alter drug exposure. Additionally, the compound exhibits pH-dependent solubility, indicating that drug-drug interactions with pH-lowering medications (such as proton pump inhibitors) must be carefully managed [1].
Immature Long-Term Data: The follow-up duration in current Phase 1/2 trials remains relatively short. In the history of BTK inhibitor development, certain adverse events (such as hypertension and atrial fibrillation) only became apparent after prolonged exposure. Longer follow-up is necessary to fully characterize the long-term safety and durability of response for BGB-16673 [1].
6. Future Perspectives
The compelling early efficacy of BGB-16673 in double-refractory CLL/SLL has led the FDA to grant it Fast Track designation for this indication [1]. Moving forward, a major focus of clinical research will be the investigation of BGB-16673 in combination regimens. Because B-cell malignancies can develop resistance through multiple pathways, targeting BTK alongside other survival pathways may yield synergistic antitumor activity and prevent the emergence of resistant clones (such as the A428D mutation) [1].
To this end, an ongoing Phase 1b/2 trial (NCT06634589) is evaluating BGB-16673 in combination with sonrotoclax (a novel BCL2 inhibitor) and zanubrutinib (a covalent BTKi) across various B-cell malignancies, including CLL [1]. Furthermore, as the therapeutic landscape expands to include cellular therapies like CAR-T and bispecific antibodies, determining the optimal sequencing of BTK degraders relative to these modalities will be a critical area of ongoing debate and investigation [1]. Ultimately, Catadegbrutinib represents a highly promising, tolerable oral therapy that may redefine the standard of care for patients with multiply relapsed CLL and SLL.
